SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Form 4 SAB Biotherapeutics, For: Feb 03 Filed by: Sullivan Eddie Joe
Form 4 SAB Biotherapeutics, For: Feb 05 Filed by: Reich Samuel J
Form 4 SAB Biotherapeutics, For: Feb 03 Filed by: Bausch Christoph Lawrence
Form 4 SAB Biotherapeutics, For: Feb 03 Filed by: Kropotova Alexandra
Form 4 SAB Biotherapeutics, For: Feb 03 Filed by: To Lucy
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.